Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk
- 1 April 2004
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 14 (4) , 239-245
- https://doi.org/10.1097/00008571-200404000-00003
Abstract
The association between vitamin D receptor (VDR) gene polymorphisms and diseases such as breast cancer, prostate cancer and osteoporosis has been extensively investigated during recent years. To date, several polymorphisms have been found in the VDR gene. In this Finnish case-control study, comprising 483 breast cancer patients and 482 healthy population controls, we investigated the association between altered breast cancer risk and two polymorphisms in the 3' end of the gene detectable with ApaI and TaqI restriction enzymes. A statistically significant difference was observed in the ApaI genotype distribution between cases and controls. Women with the VDR variant a allele containing genotypes showed a decreased risk for breast cancer [odds ratio (OR) 0.73, 95% confidence interval (CI) 0.54-0.98] compared to women with the AA genotype. This association was especially strong among women with a positive family history of breast cancer (OR 0.14, 95% CI 0.03-0.76). Moreover, there was a trend (P for trend = 0.0007) for decreased risk with increasing number of variant alleles. The lowest risk of breast cancer was seen for the women with the aa genotype (OR 0.03, 95% CI 0.003-0.31) compared to women with the AA genotype. A tendency of decreased risk of breast cancer was also observed for the TaqI T allele containing genotypes (Tt and TT) (OR 0.68, 95% CI 0.41-1.12), but because the distribution of Taql alleles in the controls missed the Hardy-Weinberg equilibrium (P = 0.01), we were unable to properly assess the potential impact of the TaqI polymorphism in breast cancer susceptibility. In conclusion, our results suggest that the VDR ApaI genotype may be an important modifier of individual breast cancer risk among Finnish women, especially if they have a positive family history of breast cancer.Keywords
This publication has 38 references indexed in Scilit:
- Identification of a novel Tru9 I polymorphism in the human vitamin D receptor geneJournal of Human Genetics, 2000
- The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal mexican-American womenJournal of Bone and Mineral Research, 1996
- Estrogens and breast cancerCarcinogenesis: Integrative Cancer Research, 1996
- Prediction of bone density from vitamin D receptor allelesNature, 1994
- Endogenous Hormones and Breast Cancer RiskEpidemiologic Reviews, 1993
- Effects of synthetic vitamin d analogues on breast cancer cell proliferation in vivo and in vitroBiochemical Pharmacology, 1992
- A Novel Vitamin D3Analog, 22-Oxa-1, 25- Dihydroxyvitamin D3, Inhibits the Growth of Human Breast Cancerin Vitroandin Vivowithout Causing Hypercalcemia*Endocrinology, 1991
- POSSIBLE ROLE FOR VITAMIN D IN CONTROLLING BREAST CANCER CELL PROLIFERATIONThe Lancet, 1989
- Cloning and expression of full-length cDNA encoding human vitamin D receptor.Proceedings of the National Academy of Sciences, 1988
- 1,25-dihydroxyvitamin D3 inhibits the clonogenic growth of transformed cells via its receptorBiochemical and Biophysical Research Communications, 1986